Alnodesertib granted fast track designation by the FDA
The ATR inhibitor alnodesertib has been granted fast track designation by the US Food and Drug Administration (FDA), biopharmaceutical company Artios Pharma Limited has announced.
Alnodesertib is a treatment for adult patients with ATM negative metastatic colorectal cancer (mCRC) in the third-line setting, in combination with a low dose of chemotherapeutic agent irinotecan. The designation is supported by encouraging results from the ongoing STELLA Phase I/IIa study, with results showing a favourable safety profile and that the drug has been well tolerated to date.
“The Fast Track designation for alnodesertib underscores its first-in-class potential for third-line mCRC patients with ATM-negative tumours,” said Mike Andriole, Chief Executive Officer of Artios. “Approximately 3,000 patients with ATM-negative third-line mCRC succumb to this disease annually in the United States, with no treatment options that specifically address this protein deficiency.”
“Alnodesertib has the potential to be the first treatment specifically for this invariably lethal disease. Additionally, we are encouraged by the durable responses this programme has demonstrated across other tumour types, highlighting its ability to target replication stress across a range of solid tumours.”
“Patients with third-line colorectal cancer face a dismal prognosis,” Ian Smith, Chief Medical Officer of Artios, added, “with current standards of care for third-line mCRC delivering response rates in the single digits.”
“These [study] results, together with activity across other solid tumours, highlight alnodesertib’s potential to deliver meaningful benefit where treatment options are limited. The FDA’s Fast Track designation recognises both the strength of our early clinical data and the urgent need for new therapies, while also providing the opportunity for enhanced interactions with the agency.”
Bruno Quinney, Content Team, DDW
